Allergan says it will shed two drugs as AbbVie takeover loomsAllergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead Share XAllergan says it will shed two drugs as AbbVie takeover loomshttps://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/
Allergan pulls breast implants after link to rare cancerAllergan has followed through on an FDA request to carry out a worldwide recall of textured breast implant Share XAllergan pulls breast implants after link to rare cancerhttps://pharmaphorum.com/news/allergan-pulls-breast-implants-after-link-to-rare-cancer/
AbbVie ducks bolt-on trend and agrees Allergan mega-mergerUS drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew Share XAbbVie ducks bolt-on trend and agrees Allergan mega-mergerhttps://pharmaphorum.com/news/abbvie-ducks-bolt-on-trend-and-agrees-allergan-mega-merger/
New paediatric use for Allergan’s biosimilar-threatened BotoxAllergan’s Botox has another clinical use after the FDA granted approval for children with upper limb spasticity. The Share XNew paediatric use for Allergan’s biosimilar-threatened Botoxhttps://pharmaphorum.com/news/new-paediatric-use-for-allergans-biosimilar-threatened-botox/
FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Collaborating to fight NASHEric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going Share XCollaborating to fight NASHhttps://pharmaphorum.com/r-d/views-analysis-r-d/collaborating-to-fight-nash/
Discontent at Allergan over CEO’s chairman role – reportThere is discontent among Allergan’s shareholders over CEO Brent Saunders’ dual role as chairman, according to press reports. Share XDiscontent at Allergan over CEO’s chairman role – reporthttps://pharmaphorum.com/news/discontent-at-allergan-over-ceos-chairman-role-report/
Allergan abandons women’s health sale plan as profit slumpsShares in Allergan fell after the company said it had swung to a loss in the last quarter Share XAllergan abandons women’s health sale plan as profit slumpshttps://pharmaphorum.com/news/allergan-abandons-womens-health-sale-plan-as-profit-slumps/
